Seres Therapeutics IPO Raises $134M on Nasdaq
June 26, 2015
Seres Therapeutics priced its initial public offering at $18.00 per share, offering 7.4 million shares and raising approximately $133.8 million. The IPO exceeded initial expectations which had targeted $100 million, with an implied fully diluted market value of $637 million.
Nestle Health Science took an estimated 18% stake in the IPO, signaling early strategic interest in the microbiome pioneer. This IPO was notable as one of the largest for a microbiome-focused biotech at the time, highlighting growing investor confidence in the therapeutic potential of the human microbiome.
Founded through work at TJHSST-connected Flagship Pioneering, Seres became a leader in microbiome medicine, ultimately achieving FDA approval for VOWST in 2023.